MetaCap

Cardio Diagnostics (CDIO) vs Anbio Biotechnology (NNNN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Anbio Biotechnology is the larger company by market cap ($145.7 million vs $4.7 million), about 30.8 times the size. Anbio Biotechnology converts more of its revenue into profit, with a net margin of 74.1% versus -43832.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDIO-18.37%NNNN-32.24%
+2%-18%-38%
Oct 7, 20261 yearNov 20, 2026
CDIO-14.44%NNNN-28.76%
+3%-16%-35%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDIO versus NNNN key metrics
MetricCDIONNNN
Share price$1.60$3.32
Market cap$4.74M$145.72M
1-day change-3.03%-9.04%
YTD return—-88.96%
1-year return—-86.02%
P/E ratio (TTM)—22.13
EPS (TTM)$-2.52$0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.82K$8.65M
Revenue growth (YoY)-57.51%+5.64%
Net income (latest FY)$-6.50M$6.40M
Gross margin—87.24%
Operating margin-43737.46%66.70%
Net margin-43832.49%74.06%
52-week high$7.91$44.73
52-week low$0.97$3.09
Distance from 52-week high-79.77%-92.58%
Average volume26.91K128.35K
Shares outstanding2.96M43.89M
Employees1527
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Anbio Biotechnology is about 30.8 times larger than Cardio Diagnostics by market value ($145.72M vs $4.74M).
  • Anbio Biotechnology is more profitable, keeping 74.1 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
  • Anbio Biotechnology grew revenue faster in its latest fiscal year (+5.64% vs -57.51%).

About Cardio Diagnostics

CDIO stock →

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees

About Anbio Biotechnology

NNNN stock →

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees

CDIO vs NNNN FAQ

Which is bigger, Cardio Diagnostics or Anbio Biotechnology?

Anbio Biotechnology (NNNN) is larger, with a market capitalization of $145.72M compared with $4.74M for Cardio Diagnostics (CDIO).

Are Cardio Diagnostics and Anbio Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons